Day: December 6, 2022

Calgon Carbon Reactivation Study Shows Removal and Destruction of PFAS

Peer-reviewed journal article details Calgon Carbon study findings Pittsburgh, PA, Dec. 06, 2022 (GLOBE NEWSWIRE) — A new study by Calgon Carbon Corporation (“Calgon Carbon”), a wholly owned subsidiary of Kuraray Co., Ltd. (TYO: 3405) (“Kuraray”), has provided a definitive response to a persistent question about the fate of PFAS during reactivation

Nucleus Software Implements Digital Lending Solution to Bank of Sydney, Empowering a Shift Towards Digital Customer Experience

The solution allows the bank to deliver faster credit decisions and automate workflows, enhancing business agility and productivity. SYDNEY, Dec. 06, 2022 (GLOBE NEWSWIRE) — Nucleus Software transforms Bank of Sydney towards digital customer experience with FinnOne neo™ solution. Bank of Sydney is an organization committed to providing genuine value

TrueBinding Highlights the Potential of TB006’s Unique Mechanism of Action as a Novel Approach for the Treatment of Alzheimer’s Disease at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Novel antibody, TB006, demonstrated improvements in cognition and function and was well tolerated in a one-month Phase 1b/2 trial in mild to severe Alzheimer’s disease (AD) patients TB006 also demonstrated improvements in PET and MR imaging, consistent with dissolution of toxic amyloid plaque shown in preclinical studies Ongoing open-label extension

Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing

Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing The Series C extension round will accelerate clinical development, manufacturing scale-up and pre-commercialization activities of Pulmocide’s lead product candidate, opelconazole Paris, France, December 6th 2022 – Jeito Capital (“Jeito”), the largest fully independent international private equity firm dedicated to healthcare and biopharma, announced today its participation in a $52 million Series C extension